Mounjaro side effects: what the latest news and safety updates mean for you

The biggest myth: 'new side effect warnings mean the medicine is unsafe'

The January 2026 MHRA Drug Safety Update on pancreatitis caused a wave of alarming coverage. What it actually said was more measured: acute pancreatitis is a known but infrequent adverse effect of GLP-1 receptor agonist medicines, and prescribers and patients should know the warning signs. That is normal post-authorisation safety practice, not a new discovery that changes the benefit-risk picture. Tirzepatide's profile was established across thousands of adults in the SURMOUNT clinical programme before it reached UK pharmacies.

What the update added in practical terms: if you develop severe, persistent stomach pain (particularly pain that moves through to your back, with or without vomiting) stop eating and drinking and get medical help the same day. That symptom pattern warrants a call to 111 or, if severe, 999. It does not warrant quietly waiting for your next prescription review.

The NHS medicines page for tirzepatide has been updated in line with this guidance and is the clearest plain-English resource for understanding what is, and what is not, cause for concern. The full side-effect profile for Mounjaro covers this in more detail if you want a thorough breakdown.

What the current evidence actually shows about common side effects

For the large majority of people, Mounjaro's side effects are gastrointestinal and dose-related. Nausea is the one mentioned most; constipation, loose stools, indigestion and burping appear frequently too. Fatigue and headache show up in trials, usually early in treatment. Injection-site reactions (a little redness or tenderness at the spot) are common enough to be routine.

These effects tend to be most noticeable in the first week or two at a new dose and then ease. Starting at 2.5mg keeps initial tolerance manageable; the graduated titration schedule exists precisely because the body adjusts better when dose changes happen slowly. If a particular dose is genuinely not tolerated, the prescriber decides whether to extend the current step or reconsider the plan, and you can read about how Mounjaro works and what the treatment journey involves if you want that broader context before starting. That is not a decision to make unilaterally by skipping a pen.

The five side effects people ask about most include nausea and fatigue specifically, worth reading before you start if you want to know what to expect at week one versus week six.

When to get medical help: the symptoms that need prompt attention

Most side effects do not need emergency input. These do.

Seek medical help promptly (same day, not at your next review) for: severe or persistent abdominal pain, especially if it reaches your back; signs of a serious allergic reaction (facial swelling, difficulty breathing, a spreading rash); symptoms of gallbladder problems (sudden sharp pain in the upper right abdomen, fever, jaundice); or significant dehydration from repeated vomiting or diarrhoea (very dark urine, dizziness on standing, inability to keep fluids down). If you are taking Mounjaro alongside medicines for your eyes or have diabetes, tell your eye specialist and diabetes team.

Call 999 or go to A&E if the reaction is severe. Call 111 if you are unsure but concerned. Do not wait for a scheduled clinical review if something feels acutely wrong.

Suspected side effects can be reported to the MHRA via the Yellow Card scheme, patients, carers and healthcare professionals can all submit reports, and every report genuinely helps the post-authorisation safety picture.

If you are experiencing something unexpected and want to discuss it, our aftercare team is available seven days a week.

Situations where side effects look different: oral contraception, HRT and surgery

This is the area where recent NHS guidance has been most specific, and where some online summaries have been incomplete. Because tirzepatide slows gastric emptying, it may reduce how reliably an oral contraceptive pill is absorbed, particularly in the early weeks of treatment. UK guidance recommends adding a non-oral method of contraception for the first four weeks of Mounjaro treatment and for four weeks after each dose increase. This applies to the pill specifically; it is not a contraindication.

For people on oral HRT, NHS England suggests discussing transdermal alternatives (patches or gels) with your GP, again because absorption via the gut may be less predictable while on tirzepatide. And if any surgical procedure is planned, tell the anaesthetist you are taking Mounjaro: delayed gastric emptying carries anaesthetic considerations that the team needs to know about in advance.

None of these are reasons to avoid treatment. They are reasons to have the conversation, which is exactly what happens during a clinical consultation. Our prescribers discuss contraception, existing medicines and upcoming procedures as a standard part of assessing suitability, and if you are wondering what side effects to expect if Mounjaro is right for you, that page sets out a realistic picture personalised to different starting points. More detail on these specific interactions is on the emerging Mounjaro safety information page, and if you have been told you experienced no reactions at a previous dose and are curious whether that pattern tends to continue, the page on why some people on Mounjaro report no side effects explains what the evidence says.